So that’s where we’ve seen a lift around the world as we brought the subcu out in accessing these new providers and new patients that are new to the franchise. On the other side, we also have some cannibalization of existing patients. So the — now we become the only product really that has both subcu and IV options, a really excellent pen, along with all the other benefits of ENTYVIO. Gut selective, long-term safety and efficacy data, and really an ideal first choice when conventional therapies fail. And so we do see some patients now that would be on the IV switching to the subcu, that ends up being net neutral to us, but it just gives more options for patients now who want to stay in the ENTYVIO family, and stay on ENTYVIO have different options for taking it.
Thank you.
Miki Sogi: Thank you.
Christopher O’Reilly: Okay. Thank you very much. Okay, since we are getting close to the end of the call, the next question will be our final question. So I’d like to call upon Ueda-san from Goldman Sachs.
Akinori Ueda: [Foreign Language] [Interpreted] This is Ueda-san, Goldman Sachs. Thank you for the opportunity. I would like to ask two questions about the business development. First of all, on page 19, you are showing this information about oncology. EXKIVITY, negative progress and ALUNBRIG, strong competition and growth and new share products are struggling in this background. Do you feel that you need to do something additional to counter this situation? That’s my first question. And the second question is in relation to that, you talked about strengthening the pipeline. So currently, what kind of franchise or what kind of phase development phase are you considering for potential in-licensing? Please share with us your current thoughts.
Christopher O’Reilly: Thank you, Ueda-san for that question. So a question around our business development plans. First of all, in oncology to supplement the portfolio, and then looking at the pipeline, which phases, which therapeutic areas. I’d like to ask Christophe to comment on this.
Christophe Weber: Thank you, Ueda-san for the question. So first, I will say that we are not looking — we just reconfirm to everyone that we are not looking at large M&A for scale purpose. So we are very competitive in all the key countries where we operate. We don’t have a scale or a competitive issue in that regard. So it’s all about portfolio pipeline, so targeted BD. On oncology, if we can bring new assets like [Indiscernible] fruquintinib that we just in-licensed, that would be terrific. So we are looking at this type of deals to complement our portfolio. We have a very attractive pipeline, but it’s more mid-stage. So many of these products in our pipeline will be launched towards the end of the decade. So if we can bring more assets to enrich our portfolio, we’ll do.
And we follow, in fact, roughly the same approach across the therapy area. Obviously, we are a leader in the GI space. So if we can bring other assets we’ll do. We shouldn’t forget that we have a very strong position in rare disease in LSDs disease, so we are looking at that. In plasma-derived therapy, there is not much to do. So it’s really about making our portfolio and pipeline and more competitive. So I think we are quite agnostic on the phase, but we are very focused on the therapy of the disease area because we want to leverage where we are strong and where we know — where we have a very strong corporate knowledge about the disease. So that’s what is guiding us for our business development strategy.
Akinori Ueda: [Foreign Language] [Interpreted] Thank you very much. That’s all from me.
Unidentified Company Representative: Thank you very much. [Foreign Language] [Interpreted] With that, I would like to conclude today’s call. Thank you very much for your presence despite your busy schedule. We’d like to ask for your continued support going forward.
